Lilly Diabetes Drug Gains FDA Approval
Lilly completed the CoLucid acquisition in March.
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe U.S. Food and Drug Administration has approved a new drug developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. Lilly says Synjardy XR will improve blood sugar in adults with type 2 diabetes when used with diet and exercise.
Lilly says the approval is based on results from multiple clinical trials. The drug is the eighth treatment developed through the partnership between the two companies to be approved by the FDA, according to Paul Fonteyne, chief executive officer of Boehringer Ingelheim.
"Adults with type 2 diabetes often take multiple medications, sometimes more than once a day, to manage their condition," said Fonteyne. "With Synjardy XR, adults with type 2 diabetes now have another convenient daily option to help them reach their glycemic goals, whether they are already being treated or are just at the beginning of their treatment."
It’s the second FDA approval for a type 2 diabetes treatment for the two companies this month. Last week, Lilly announced its drug Jardiance had received new approval to be used to reduce the risk of cardiovascular death among adults with type 2 diabetes and established cardiovascular disease.